Lastet Etoposide 100 mg Cold chain · Storage +2…+8 °C

Indicated for the treatment of:

• Small Cell Lung Cancer (SCLC): Often used in combination with Cisplatin.
• Testicular Cancer: Refractory non-seminomatous germ cell tumors.
• Hodgkin's and Non-Hodgkin's Lymphomas.
• Acute Myeloid Leukemia (AML).

⚠️ For Slow Intravenous Infusion ONLY.

Administration Guidelines:

• 🚫 NO Rapid Injection: Rapid push causes severe hypotension (low blood pressure). Administer over at least 30–60 minutes.
• 💧 Must be Diluted: Dilute the concentrate in 0.9% Sodium Chloride or 5% Dextrose. Final concentration should not exceed 0.4 mg/ml to prevent precipitation.

Warning: Extravasation (leakage under skin) causes severe tissue necrosis. Do not administer IM or SC.

• Severe bone marrow depression (Neutrophils < 1500/mm³, Platelets < 75,000/mm³).
• Severe hepatic or renal impairment.
• Hypersensitivity to Etoposide.
• Pregnancy.

Adverse reactions associated with IV administration:

• Hypotension: Related to rapid infusion rate.
• Myelosuppression: Leukopenia is the dose-limiting toxicity. Monitor blood counts.
• Alopecia: Reversible hair loss occurs in most patients.
• Nausea and vomiting.